Security National Bank Takes Position in Pfizer Inc. (NYSE:PFE)

Security National Bank purchased a new position in shares of Pfizer Inc. (NYSE:PFEFree Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 2,252 shares of the biopharmaceutical company’s stock, valued at approximately $65,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 8.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock valued at $2,985,783,000 after purchasing an additional 8,473,686 shares during the last quarter. Morgan Stanley increased its stake in shares of Pfizer by 0.4% in the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after acquiring an additional 348,628 shares during the last quarter. Norges Bank purchased a new position in shares of Pfizer during the 4th quarter worth $2,129,927,000. Massachusetts Financial Services Co. MA grew its holdings in shares of Pfizer by 13.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock valued at $1,972,300,000 after purchasing an additional 8,298,920 shares during the period. Finally, Invesco Ltd. increased its position in Pfizer by 30.9% during the third quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock worth $797,901,000 after purchasing an additional 5,678,004 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. BMO Capital Markets restated an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley increased their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $35.86.

Check Out Our Latest Stock Report on PFE

Pfizer Stock Down 0.8 %

Shares of NYSE:PFE traded down $0.22 during trading on Friday, hitting $28.58. The company’s stock had a trading volume of 27,526,200 shares, compared to its average volume of 33,056,490. The company has a market capitalization of $161.95 billion, a PE ratio of -476.25, a P/E/G ratio of 1.13 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $40.37. The business has a 50 day moving average price of $27.50 and a two-hundred day moving average price of $27.88.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. Pfizer’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.23 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.88%. Pfizer’s payout ratio is -2,799.53%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.